Straits Times Index
3,286.67 -1.08 (-0.03%) Nikkei
37,780.35 +151.87 (+0.40%) Hang Seng
17,588.14 +303.60 (+1.76%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,414.35 +120.38 (+0.19%) CMC Crypto 200
1,392.30 +9.73 (+0.70%)
Olema Pharmaceuticals, Inc. (OLMA)
After hours:
- GlobeNewswire
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monda
- GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company's common stock, effective as of April 1, 2024. These awards were approved by the Compensation Com
- GlobeNewswire
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 2023; top-line results expected in 202660-patient Phase 2 studies in combination with each of ribociclib and palbociclib are fully enrolled; palazestrant-ribociclib clinical update to be presented at ESMO Breast Cancer Annual Congress 2024, May 15-17, 2024, in BerlinCash, cash equi
